天際股份(002759.SZ):擬以4.6億元收購譽翔貿易100%股權 間接控股新特化工
格隆匯8月3日丨天際股份(002759.SZ)公佈,公司於2023年8月3日與支建清、王正元、徐衞、韋建東、周帥、鄭健、顏玉紅、趙東學共8名交易對方(簡稱“交易對方”)及常熟市譽翔貿易有限公司(簡稱“譽翔貿易”)、常熟新特化工有限公司(簡稱“新特化工”,系譽翔貿易的全資子公司)簽訂附條件生效的《股權收購協議》,擬以人民幣4.6億元的價格收購交易對方持有的譽翔貿易100%的股權,進而間接收購新特化工100%的股權(簡稱“本次交易”)。本次交易完成後,公司將持有譽翔貿易100%的股權並間接持有新特化工100%的股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.